Startup revolutionizes diagnostics in dermatology
Dermagnostix closes seven-figure seed round
Dermagnostix revolutionizes diagnostics in dermatology with its fully auto-mated "lab-in-a-box" system, which allows the technically valid performance of complex molecular assays. "Modern molecular diagnostics is a prerequisite for implementing precision medicine in dermatology. It not only supports conventional diagnostics, but also makes it possible to predict individual therapy response and course of disease," explains CEO, dermatologist and co-founder Dr Natalie Garzorz-Stark, adding: "Unfortunately, manual performance of complex DNA- and RNA-based assays is time-consuming, error-prone and requires expertise, which is why large implementation could not be achieved to date. A few years ago, the LabDisk platform developed at Hahn-Schickard provided the ideal technical solution for the first molecular test "PsorEx", patented by Helmholtz Munich and TU Munich, to distinguish between psoriasis and eczema.
Symbolic image
pixabay.com
The idea of Dermagnostix was born. "Our LabDisk technology is based on smart centrifugal microfluidics and makes it possible to measure 40 markers and more simultaneously within 60 to 90 minutes, even in solid tissue such as the skin," describes CTO and co-founder Dr Katharina Dormanns, who previously headed the LabDisk platform group at Hahn-Schickard in Freiburg.
The degree of innovation of the system and also its application for diagnostics not only convinced the investors in this seed round, but was also recognized by numerous juries. With the help of competitive third-party funds of 3 million euros in the pre-founding phase, the system was developed to the functional model stage. Numerous prizes in business competitions and admission in exclusive networks such as BayStartUP, WECONOMY and CDL Oxford have enormously expanded the reach of the still young spin-off within a few months since its establishment in 2021.
"It is a great advantage and very motivating that we have gained experienced and well-connected investors with regulatory, financial and medical expertise to support us in our mission to bring molecular diagnostics in dermatology to everyone, everywhere," the founders enthuse. The seven-figure sum will now be used to bring the system with the first test PsorEx-LabDisk to market maturity. Dr Helmut Laaff, dermatopathologist from Freiburg and investor in the seed round, is already very excited about being able to integrate the system in his own laboratories and to contribute to the development of the portfolio.
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
